MHUA vs. PAVM, NEPH, LYRA, PYPD, GCTK, TTOO, NXGL, MBOT, SSKN, and PETV
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include PAVmed (PAVM), Nephros (NEPH), Lyra Therapeutics (LYRA), PolyPid (PYPD), GlucoTrack (GCTK), T2 Biosystems (TTOO), NEXGEL (NXGL), Microbot Medical (MBOT), STRATA Skin Sciences (SSKN), and PetVivo (PETV). These companies are all part of the "surgical & medical instruments" industry.
PAVmed (NASDAQ:PAVM) and Meihua International Medical Technologies (NASDAQ:MHUA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Meihua International Medical Technologies has higher revenue and earnings than PAVmed.
In the previous week, PAVmed had 6 more articles in the media than Meihua International Medical Technologies. MarketBeat recorded 6 mentions for PAVmed and 0 mentions for Meihua International Medical Technologies. Meihua International Medical Technologies' average media sentiment score of 0.56 beat PAVmed's score of 0.00 indicating that PAVmed is being referred to more favorably in the media.
19.9% of PAVmed shares are owned by institutional investors. Comparatively, 1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 12.6% of PAVmed shares are owned by insiders. Comparatively, 66.6% of Meihua International Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
PAVmed currently has a consensus target price of $21.00, indicating a potential upside of 1,073.18%. Given Meihua International Medical Technologies' higher probable upside, analysts clearly believe PAVmed is more favorable than Meihua International Medical Technologies.
PAVmed received 201 more outperform votes than Meihua International Medical Technologies when rated by MarketBeat users.
PAVmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Meihua International Medical Technologies has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Meihua International Medical Technologies has a net margin of 0.00% compared to Meihua International Medical Technologies' net margin of -2,037.67%.
Summary
PAVmed beats Meihua International Medical Technologies on 8 of the 13 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MHUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Meihua International Medical Technologies Competitors List
Related Companies and Tools
